<DOC>
	<DOC>NCT01526616</DOC>
	<brief_summary>The investigators examined whether a combined therapy with low-dose spironolactone plus metformin is more effective than metformin alone in 52 overweight/obese Polycystic Ovary Syndrome (PCOS) patients.</brief_summary>
	<brief_title>Spironolactone Plus Metformin in Polycystic Ovary Syndrome</brief_title>
	<detailed_description>In the present prospective, randomized study, we evaluated the efficacy of a combined therapy with metformin and low-dose spironolactone as compared to metformin alone on the clinical and endocrine-metabolic alterations of PCOS patients.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Overweight/obese patients with PCOS Other causes of hyperandrogenism and Use of drugs including: oral contraceptive antihypertensive agents antidiabetic drugs agents for weight loss</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>PCOS</keyword>
	<keyword>metformin</keyword>
	<keyword>spironolactone</keyword>
	<keyword>metabolic syndrome</keyword>
	<keyword>hyperandrogenism</keyword>
</DOC>